Articles tagged with Lung Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers found that a virulent strain of H. pylori reduced the risk of deaths from stroke by 55% and lung cancer by 45%. The study, which analyzed data from nearly 10,000 individuals, also found no association between H. pylori positivity or cagA-positivity and all-cause mortality.
A new study proposes a possible pathway to benefit from drugs for lung cancer prevention by identifying microRNA-34c as a surrogate endpoint. Changes in its expression six months after treatment correlate with benefit from the drug, potentially speeding up the pace of discovery and bringing new agents to market.
A study of 722 patients found that those taking beta-blockers for other conditions lived longer after receiving radiotherapy. The use of beta-blockers improved survival rates without disease spreading or recurring, but not locoregional progression-free survival.
Researchers analyzed over 400 patient records to find that the proportion of early-stage lung cancer cases identified by CT scans increased by almost 50% during a recent 10-year period. However, only half of these cases would meet criteria for lung cancer screening under existing guidelines.
A new study validates the IASLC/ATS/ERS classification for lung adenocarcinomas among Japanese patients, revealing prognostic value in histologic subtypes. The classification identifies specific molecular markers, such as EGFR and KRAS mutations, associated with prognosis and treatment outcomes.
A recent study published in the Journal of Thoracic Oncology found that COPD is not an independent risk factor for lung cancer. Researchers associated COPD with lung cancer, but attributed this link to smoking and ascertainment bias, highlighting the need for lung cancer screenings when diagnosing COPD.
A recent study found immunohistochemistry to be a reliable and accurate method for detecting ALK rearrangement in non-small cell lung cancer. The technique outperformed fluorescence in situ hybridization, which is currently the standard but time-consuming method.
Recent advancements in lung cancer treatment focus on targeting specific genetic mutations, resulting in improved patient response rates (70-80%) compared to traditional chemotherapies. However, challenges remain in securing funding for clinical trials and staying ahead of the disease's rapid mutation rate.
A team of researchers has discovered that the cellular reprogramming gene SOX2 is directly regulated by the tumor suppressor CDKN1B(p27) gene, which is also associated with cancers such as lung and pituitary cancer. The study also highlights the potential role of adult stem cells in cancer.
Routine use of upper endoscopy for most GERD patients does not improve patient health and may lead to unnecessary interventions. Computer alerts in HIV care improve patient outcomes by notifying providers of adverse events or missed appointments, leading to better follow-up practices.
Researchers have found that targeting resistant lung cancer 'pockets' with focused radiation can prolong disease control in patients who initially respond to crizotinib or erlotinib. This approach showed significant benefits in patients whose cancers progressed in the brain, where the drugs are less effective.
Lung cancer researchers at St. Joseph's Hospital and Medical Center identified a gene involved in non-small cell lung cancer tumor growth, leading to potential new treatments that inhibit tumor growth. The study found that the Fn14 gene is elevated in NSCLC tumors and promotes migration and invasion.
Researchers at Thomas Jefferson University have developed a new real-time tracking technique that can better predict and track tumor motion during radiotherapy, sparing healthy tissue. The technique has shown to deliver higher levels of radiation to moving tumors while reducing dose to critical organs.
A study published in the Journal of Thoracic Oncology found that denosumab was associated with significantly improved overall median survival in lung cancer patients, including those with non-small-cell lung cancer and small-cell lung cancer. The treatment also showed improved survival in patients with squamous cell carcinoma.
Researchers have successfully genotyped 344 NSCLC specimens with a median turnaround time of 31 days, enabling targeted therapy. This study's findings highlight the potential for large-scale genomic testing to transform lung cancer treatment.
Researchers found that local ablative therapy and continuation of targeted drugs can prolong disease control by up to 6.2 months in patients with EGFR mutations or ALK rearrangements. The study's findings suggest a new approach to treating NSCLC after progression, particularly for patients with oligoprogressive disease.
A University of Cincinnati research team isolated and grew lung cancer stem cells in a preclinical model, offering a new avenue for investigating immunotherapy options that specifically target stem cells. This breakthrough could lead to the development of novel therapies targeting these cells and improving treatment outcomes.
A large-scale genome-wide association study found three genetic regions associated with lung cancer risk in Asian female never-smokers. The discovery provides evidence that common inherited genetic variants contribute to an increased risk of lung cancer among this population.
A study of 1.3 million women found that quitting smoking can significantly reduce the risk of premature death, with smokers who stop before age 30 avoiding nearly all excess risk. The risks associated with smoking are substantial and increase with the amount smoked, highlighting the importance of quitting to extend life.
Researchers developed models from PLCO data to predict smoking status, finding that relapse and continued smoking are linked to demographic and tobacco-related characteristics. The models suggest variables like longer-term smokers, recent quitters, and pipe or cigar smokers are at higher risk for relapse.
Researchers found that JHQG significantly prolonged survival in patients with non-small cell lung cancer (NSCLC), improved quality of life and activity capacity in IPF patients, and reduced fever in influenza patients compared to standard care and placebo.
Patients undergoing non-small cell lung cancer (NSCLC) resection who take statins may experience improved overall survival and reduced risk of recurrence. Statin use was associated with a significantly lower local recurrence rate compared to non-statin users.
A long-term study found that radiotherapy after surgery significantly improves biochemical progression-free survival and local control for high-risk prostate cancer patients. However, its effects on clinical progression-free survival and overall survival are less clear.
A study published in the Journal of Thoracic Oncology found that VeriStrat can predict response to erlotinib, but does not provide a survival benefit. The test showed a significant difference in median survival between good and poor responders, with good responders experiencing longer survival on erlotinib.
A study published in the Journal of Thoracic Oncology found that fit elderly patients with non-small cell lung cancer can benefit from salvage targeted therapy without increased toxicity. The study analyzed data from 255 patients and showed no difference in response rates or progression-free survival between age groups.
Scientists at the University of York have discovered a protein called Ciz1 that is present in lung cancers, even in early stages. A simple blood test using this protein could help diagnose lung cancer without invasive procedures.
A study analyzing the International Mesothelioma Interest Group (IMIG) staging system for malignant pleural mesothelioma (MPM) reveals areas for potential revision. The current system distinguishes among T and N categories, but qualitative T descriptors may not be applicable to clinical staging.
A variant in the NFKB1 gene has been associated with a 44% reduced risk of lung cancer, according to a new analysis of 378 patients and 450 healthy controls. The study suggests that inflammation may play a role in lung cancer development.
A phase III trial shows that crizotinib is more effective than standard chemotherapy in response rates and progression-free survival, with improved quality of life. The study compared 347 patients with previously treated ALK-positive lung cancer and found significant benefits for those on the crizotinib arm.
Several new first-in-human studies for drugs targeting a range of cancers have shown promising results, including the development of MEK-, MET- and HSP90 inhibitors as well as immunotherapeutic strategies. Studies have demonstrated significant activity in ALK-positive lung cancer resistant to crizotinib and other targeted therapies.
A post-hoc analysis of the phase III MISSION trial suggests that patients with EGFR-mutant tumors may benefit from sorafenib, which showed improved progression-free survival and disease control rates. In contrast, median overall survival was similar between treatment groups.
A blood test developed by Kansas State University researchers can accurately detect the beginning stages of breast and non-small cell lung cancer. The test works by detecting increased enzyme activity in the body, with a 95% success rate in detecting cancer in participants.
Researchers found that genetic diversity in natural killer cells contributes to lung cancer susceptibility. In mice, manipulating the immune system can significantly block tumor growth. The study suggests a key role for natural killer cells in lung cancer, potentially offering new targets for therapy.
Recent breast cancer research at ESMO 2012 emphasizes the importance of avoiding weight gain after treatment to reduce recurrence risk. Additionally, studies focus on the correlation between body mass index and prognosis, as well as lung cancer in never-smoking women, highlighting hormonal factors and high incidence of EGFR mutation.
A pilot study found that breath testing can accurately discriminate between benign and malignant pulmonary nodules. The technique, using volatile organic compounds and chemical nanoarrays, identified 53 malignant and 19 benign nodules with high accuracy.
Two new studies have identified novel genes and patterns of mutations involved in lung cancer, with significant differences found between smokers and non-smokers. These findings could lead to targeted therapies to improve survival rates and outcomes for lung cancer patients.
Crizotinib successfully shrinks tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer. The treatment showed a high overall response rate of 60% and improved median progression-free survival.
Patients with stage I non-small cell lung cancer (NSCLC) who received radiation therapy had an increased median survival of 21 months compared to 16 months. The percentage of patients not receiving treatment declined from 20 percent to 16 percent between 1999-2003 and 2004-2008.
Researchers found that adding bavituximab to docetaxel chemotherapy improves response rates, progression-free survival, and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients. The study showed a doubling of the overall response rate compared to the control arm.
A study of 168 Stage III NSCLC patients found that married women had the best three-year survival rate of 46 percent, while single men had the worst rate of 3 percent. Married patients generally had improved survival rates compared to single patients, with 33 percent vs. 10 percent.
Researchers found that standard chemotherapy with paclitaxel, carboplatin, and bevacizumab is equally effective as an experimental regimen in treating advanced non-squamous non-small cell lung cancer. The study suggests that both regimens are tolerable but have different toxicities.
A study of 14,829 Hispanic lung cancer patients from the California Cancer Registry found that foreign-born Hispanics have an even lower risk of death due to improved socio-economic factors and neighborhood conditions. This contradicts the traditional 'Hispanic paradox' by highlighting the positive impact of social factors on survival.
A recent study published in the University of Maryland Medical Center found that married lung cancer patients have a higher survival rate compared to single patients. The researchers believe that social support from spouses is a key factor contributing to improved survival rates for married lung cancer patients.
The study found an increase in non-smokers developing lung cancer, particularly women, and a shift towards adenocarcinoma. Researchers attributed this change to improved diagnostic techniques and management of lung cancer.
A Phase I/II trial tests the safety and efficacy of PR610 in patients with advanced cancer. The study aims to deliver a targeted approach, activating the compound in tissues with low oxygen levels characteristic of many cancers.
A recent University of Colorado Cancer Center case study found a patient with ALK+ lung cancer who tested negative for the EML4-ALK fusion gene using the FDA-approved FISH assay, yet showed dramatic response to crizotinib. Next-gen sequencing revealed genetic shards that may have avoided detection by the test.
A lung cancer risk prediction model developed at the University of Liverpool has been shown to be a viable tool for selecting high-risk individuals. The model was tested in international datasets and found to be more effective than smoking duration or family history alone in predicting individuals at risk.
Recent studies suggest that colonoscopy-related factors are more predictive of colorectal cancer risk than polyp characteristics. High levels of lead exposure also pose significant health risks, even at low blood lead levels. Meanwhile, a new lung cancer screening model shows high accuracy in identifying patients who will benefit from ...
Researchers have identified an experimental drug, GSIs, that blocks Notch and prevents lung cancer growth in mice without treatment-related side effects. This discovery brings new clues for the treatment of lung cancer and is being tested in co-clinical trials.
Researchers have identified how EPHA3 gene mutations may promote lung cancer. The study found that loss of the gene diminishes its tumor-suppressive effect, potentially sparking tumor growth. The findings suggest that therapies targeting a downstream pathway may be beneficial for tumors with mutant EPHA3.
Scientists investigate the use of novel AKT inhibitor MK-2206 in combination with erlotinib as a second-line defense for patients with non-small cell lung cancer (NSCLC) who have developed resistance to erlotinib. A Phase II trial has shown promising initial results.
Researchers from the British Columbia Cancer Research Center analyzed lung tumors exposed to arsenic, highlighting genetic and epigenetic changes driving carcinogenesis. These findings may help prevent arsenic-related cancer in regions with low exposure levels.
Researchers are developing a multiple marker test in peripheral blood to detect lung cancer, promising an earlier diagnosis. The test discriminated between healthy donors and patients with non-small cell lung cancer (NSCLC) with high accuracy.
Chronic obstructive pulmonary disease (COPD) increases lung cancer risk through a novel mechanism involving long-term oxygen depletion and HIF-2a tumor growth signaling. COPD-induced signals may be susceptible to prevention or treatment with VEGFR-2 and EGFR inhibitors.
A new rehabilitation program developed by Michigan State University's Amy Hoffman uses the Nintendo Wii-Fit Plus to promote light-intensity walking and balance exercises. The program has shown excellent improvement in reducing cancer-related fatigue levels over time.
Researchers at Kaiser Permanente Southern California identified 7,112 patients with lung nodules using existing medical records. They developed an automated method that classifies nodules with 96% sensitivity and 86% specificity compared to clinician review.
Researchers at Mayo Clinic found that early-stage lung cancer cells use a biological process called epithelial-mesenchymal transition (EMT) to bypass growth controls and enable uncontrolled growth. This discovery offers new clues for a potential approach to treating lung and possibly other cancers as early as possible.
Researchers identify microRNA-320a as a key regulator of glycolysis in tumors and unused muscles, potentially leading to new treatments for lung cancer and improving ventilator recovery. This discovery offers a significant therapeutic leap for numerous diseases and health conditions.
Researchers at UCSF have discovered that a human protein called AXL drives resistance to Tarceva, which suggests that blocking the protein may prevent resistance to the cancer drug. This discovery may lead to better treatments involving precision medicines that combine Tarceva with new drugs designed to block AXL.
Researchers discovered that combining EGFR inhibitors with Wnt pathway inhibition can improve the durability of lung cancer remission. The Wnt pathway allows lung cancer cells to escape from EGFR-targeted therapy, but disrupting this pathway could lengthen the usefulness of existing treatments.